Introduction
The proliferation of many hematopoietic precursor cells is promoted by interleukin-3 (IL-3), granulocyte/macrophage colony-stimulating factor (GM-CSF), as well as other growth factors. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] The murine IL-3/GM-CSF dependent FDC-P1 cell line was isolated from the bone marrow of a normal DBA/2 mouse and resembles cells with a CFU granulocyte/ macrophage morphology. 9 The loss of cytokine dependency by hematopoietic cells may be an important factor in the development of leukemia.
1,2 Spontaneous factor-independent cells are rarely recovered from this cell line which makes it an attractive model system to analyze the effects various oncogenes have on signal transduction and leukemogenesis. [10] [11] [12] [13] IL-3 and GM-CSF exert their biological activity by binding to the IL-3 and GM-CSF receptors respectively (IL-3R and GM-CSFR). [1] [2] [3] [4] [5] [6] [7] [8] [14] [15] [16] These receptors activate a Janus (Jak2) protein tyrosine kinase which leads to the phosphorylation and dimerization of signal transducers and activators of transcription (STATs). In addition to Jak activation, receptor ligation promotes phosphorylation of the Shc protein. Shc then recruits the Grb2/Sos complex to the ␤ c chain resulting in stimulation of Ras (see Figure 1 ). Activated Ras promotes the sequential activation of Raf, MEK and MAP (ERK1 and ERK2) kinases. 1 Certain cytokines and interferons, stimulate Jak1 activity which can activate the Raf kinase pathway indicating that there is cross-talk between these two major signaling pathways. [15] [16] [17] [18] Moreover for optimal activation of STAT DNA binding activity, STAT dimers must be phosphorylated on key serine residues. This serine phosphorylation enhances STAT dimer nuclear translocation and is in some cases carried out by the MAP kinases ERK1 and ERK2. [15] [16] [17] Thus these signal transduction pathways are interconnected and often regulate each other.
There are three related raf genes in mammals: A-raf, B-raf and raf-1. 1, 19 The Raf proteins have been dissected into three different functional domains; CR1, CR2, and CR3. The CR1 region has the binding site for an activated Ras protein. 1, 18 The CR2 region negatively regulates the Raf kinase domain (CR3) which is located in the carboxyl-terminal half of the Raf protein. Raf proteins transmit their regulatory signals to MEK1, a dual specificity serine/threonine and tyrosine kinase which phosphorylates the downstream MAP kinases. 1, [20] [21] [22] [23] [24] The MAP kinases ERK1 and ERK2 can phosphorylate other kinases (eg p90 Rsk ) or transcription factors (eg CREB, Elk) which enter the nucleus and regulate gene expression. [25] [26] [27] [28] [29] [30] [31] N-terminal deleted forms of Raf and MEK1 proteins result in activated oncoproteins presumably due to the aberrant stimulation of downstream kinases, transcription factors and molecules involved in the prevention of apoptosis. [32] [33] [34] [35] [36] The efficiencies of hematopoietic cell transformation by activated Raf oncoproteins are much lower than that observed with v-Ha-Ras and other oncoproteins. 13, 16, 37 The nature of the inability of Raf to abrogate the cytokine dependency of most hematopoietic cells has not been elucidated. We are interested in the transforming capacity of Raf because it is located at pivotal positions in both signal transduction as well as apoptotic pathways.
The BCL2 gene has been described as a repressor of cell death. [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] This gene was isolated from the chromosomal breakpoint of a t(14;18)-bearing follicular B cell lym-
Figure 1
Signal transduction and anti-apoptotic pathways induced by cytokines. The GM-CSF cytokine is indicated in red. Inactive signal transduction molecules are indicated in maroon, activated signal transduction molecules are indicated in green. The sites where the activated ⌬Raf:ER and ⌬MEK1:ER oncogenes affect signal transduction are indicated in red. The inactive GM-CSF receptor is indicated in maroon, the activated cytokine receptor is indicated in yellow. Pro-apoptotic molecules are indicated in brown, anti-apoptotic molecules are indicated in dark blue. Tyrosine phosphorylated proteins are indicated with a black P in a white circle. Serine/threonine phosphorylated proteins are indicated by a red P with a white circle around it. The 14-3-3 family of chaperonin proteins is indicated in black. The sites of interaction of the MEK1 inhibitor is indicated by a black oval and a minus sign. The sites where the Cis family of proteins (black oval) can inhibit cytokine-induced signal transduction are indicated by a minus sign. The sites of activation of the Src family of kinases are indicated in a yellow box and arrows. The interactions of kinases with anti-apoptotic molecules are indicated. The interactions, which result in the induction of apoptosis, are indicated with skull and cross bones. The interactions that result in the prevention of apoptosis are indicated with skull and cross bones with a red X through them. A similar scenario would occur after ligation of the IL-3 receptor with IL-3. The induction of autocrine GM-CSF transcription by the activated Raf and MEK oncoprotein is indicated.
phoma. 38, 39 B cells bearing this translocation exhibit increased production of BCL2 protein and extended cell survival. 38, 39 BCL2 has been shown to protect hematopoietic cell lines from apoptosis following growth factor withdrawal. 42 Cytokine stimulation has been documented to suppress apoptosis via different mechanisms. The carboxyl region of the IL-3/GM-CSF/IL-5 R ␤ c chain has been associated with the prevention of apoptosis. 1, 8, 43 Stimulation of appropriate target cells by IL-3 leads to phosphorylation of Bad. 1, 15, [48] [49] [50] [51] Bad may become phosphorylated on either serine residues 112 or 136. Bad is phosphorylated on serine 112 via the MAPK or PI3K signal transduction pathways. The serine residue 136 may be reserved only for the phosphorylation by the PI3K pathway. 48, 51 Unphosphorylated Bad normally forms heterodimers with anti-apoptotic factors, such as Bcl-X L or BCL2. Phosphorylation of Bad releases Bad from Bcl-X L and BCL2 thereby allowing Bcl-X L and BCL2 to bind Bax, resulting in the prevention of apoptosis. The kinase(s), which directly phosphorylates Bad, is unknown, however, Raf, ERK2, p90 Rsk , Akt (PKB) and protein kinase A (PKA) can phosphorylate Bad. [47] [48] [49] [50] [51] PhosLeukemia phorylated Bad is bound and sequestered by the 14-3-3 family of proteins preventing its interaction with Bcl-X L or BCL2 (see Figure 1 ). Recent evidence indicates that ERK2, can phosphorylate BCL2 on serine residue 70 and this results in an anti-apoptotic response. 15, 38, 44, 52, 53 Furthermore, BCL2 is phosphorylated after treatment of cells with chemotherapeutic drugs such as taxol [53] [54] [55] [56] [57] [58] [59] and retinoic acid. These BCL2 phosphorylation events are associated with cell death. The time frames of these phosphorylation events are different as cytokines stimulate BCL2 phosphorylation early after treatment, whereas treatment with microtubule destabilizing drugs such as taxol result in phosphorylation of BCL2 later in the G 2 /M transition. [53] [54] [55] [56] Thus regulation of BCL2 is complex with some phosphorylation events resulting in anti-apoptotic effects, whereas others are associated with cell death.
v-Raf has been shown to suppress apoptosis by IL-3 withdrawal in the IL-3-dependent 32D.3 cell line. 57, 58 Another study in these cells demonstrated that BCL2 could be coimmunoprecipitated with v-Raf suggesting a functional link between the Raf kinase and the BCL2 protein in the sup-Leukemia pression of apoptosis. 59 Bag-1, discovered for its ability to interact with BCL2, also forms complexes with Raf-1. 60 A complex comprised of BCL2, Raf-1, and Bag-1 proteins has been hypothesized either to activate a kinase on the mitochondrial membrane or to target other kinases to the mitochondrial membrane. 61 Recently ERK2 has been shown to localize to the mitochondrial membrane. 44, 61, 62 The influence of Raf on apoptosis could lead to information of clinical value. Suppression of apoptosis in neoplastic cells is being considered as a means by which transformed cells avoid the activity of apoptosis-inducing chemotherapeutic regimens. BCL2 has also been shown to influence drug resistance and the interactions between Raf-1 and BCL2 implicate the Raf kinases in drug resistance. Thus, the study of signal transduction pathways involving Raf kinases are not only important for understanding normal cell signaling, but also may lead to development of treatments that circumvent drug resistance in leukemic cells.
Materials and methods

Cell lines and growth factors
Cells were maintained in a humidified 5% CO 2 incubator with Iscove's modified Eagle's medium (IMEM, Life Technologies, Gaithersburg, MD, USA) complemented with 5% fetal bovine serum (BCS) (Atlanta Biologicals, Atlanta, GA, USA). The IL-3/GM-CSF dependent murine myeloid cell line FDC-P1 9 was cultured in this medium supplemented with 10% WEHI-3B(D − ) conditioned medium (WCM) as a source of IL-3. Estradiol-dependent FD/⌬Raf:ER + BCL2 cells were grown in IMEM + 5% FCS + 1 m ␤-estradiol (Sigma, St Louis, MO, USA).
In some cases ⌬Raf:ER-infected cells were also cultured with 4-OH tamoxifen, also dissolved in ethanol (4-HT, Sigma). 4-HT is an estrogen-receptor antagonist that activates the ⌬Raf:ER fusion proteins. [32] [33] [34] [35] [36] [37] ⌬Raf:ER-infected cells were also treated with the MEK1 inhibitor PD98059 (New England Biolabs (NEB), Beverly, MA, USA) 63, 64 which was dissolved in dimethyl sulfoxide (DMSO, Sigma). Control cultures were set up with DMSO and either cytokine or ␤-estradiol to measure the toxicity of the solvent. Cells were in some cases treated with the PKC-inducing agent, 10 to 20 nm phorbol-12-myristate-13-acetate (PMA, Sigma) which was dissolved in DMSO.
Retroviral infection of cells
Plasmid DNAs containing recombinant retroviruses were transfected into the retroviral packaging cell lines 2 or PA317 with lipofectin (Life Technologies) and retroviruses were passed sequentially from one cell line to the other to amplify their titers as described.
6,11-13 FDC-P1 cells were infected with viral stocks as described. 6, [11] [12] [13] The ⌬A-Raf:ER, ⌬B-Raf:ER, ⌬Raf-1:ER, and a kinase-inactive ⌬Raf-1[301]:ER were contained in the pBP3puro retroviral vector which encodes resistance to puromycin. 34 Cells were also infected with a ⌬Raf-1:ER which was ligated to the green fluorescent protein (GFP). 65 Puro r cells were isolated by culture in medium containing 1 g/ml puromycin (Sigma). Some FDC-P1 cells were infected with either LNL6, an empty retroviral vector containing neo r , 66 or BCL2 contained in a neo r vector. 42 neo r FDC-P1 cells were isolated by selection in medium containing G418 (2 mg/ml, Life Technologies). The nomenclature of the FDC-P1 cells is FD/⌬Raf-1:ER, FD/⌬A-Raf:ER, FD/⌬B-Raf-1:ER, for cells infected with the ⌬Raf-1:ER, ⌬A-Raf:ER, or ⌬B-Raf:ER viruses, respectively. After the ER is the designation + BCL2 or + LNL6 for cells subsequently infected with the BCL2 and LNL6 retroviruses and whether the cells are IL-3 dependent (IL3) or estrogen-responsive (Est). Estrogen-responsive growth in these cases is proliferation promoted by the activated ⌬Raf:ER. C refers to a clone isolated by limiting dilution and pool refers to a pool of cells.
Assays of cell growth: cell growth curves, [
3
H]-thymidine incorporation and autocrine growth factor synthesis
Cells were washed three times with phosphate buffered saline (PBS) before being set up for growth curves or proliferation assays. Growth curves were performed in 5 ml of medium with the indicated supplements in T25 tissue culture flasks (Corning, Elmira, NY, USA). Cell proliferation assays were performed in 96 well flat bottom plates (Corning) with initially 10 4 cells/well that were incubated for 1 day in the presence of the indicated supplements. The supplements could include different dilutions of ␤-estradiol, tamoxifen, IL-3 or various concentrations of filter-sterilized cell supernants to determine whether or not the cells were producing autocrine growth factors. In some cases the supernatants were incubated with different concentrations of antibodies to IL-3 or GM-CSF (R&D Systems, Minneapolis, MN, USA) for 1 h before the indicator cells were added to determine which cytokine the cells were expressing. Also, in some cases the cytokine producing cells were incubated with the ␣IL-3 and ␣GM-CSF antibodies to determine the effects of these antibodies on cell growth. During the last 6 h of incubation, cellular proliferation was assayed by adding [ 3 H]-thymidine (6.7 Ci/mmol, NEN, Boston, MA, USA) as described. 6, [11] [12] [13] 
Analysis of cell cycle distribution
Cell pellets were prepared from cells isolated at the appropriate incubation times which were resuspended in PBS and then fixed in 70% ethanol overnight. The next day the cells were collected by centrifugation and washed with PBS containing 1% BSA. The cell pellets were resuspended in 0.5 ml of solution containing propidium iodide, Rnase and Triton X-100 and stained for 30 min in the dark. The cell suspension was passed through a 25-gauge needle before cell cycle analysis which were performed on a Becton Dickinson FACS analyzer. The percentage of cells in different phases of the cell cycle was statistically estimated using a ModFit 5.02 computer program.
Analysis of GFP⌬Raf-1:ER protein expression
The expression of the GFP/⌬Raf-1:ER protein was monitored by FACS analysis. The cells were washed once with PBS and then analyzed for fluorescence intensity on the Becton Dickinson FACS analyzer. Uninfected FDC-P1 and Raf-responsive FD/⌬Raf-1:ER(Est)c2 cells were used as negative controls since they lacked the GFP moiety.
Polymerase chain reaction amplification of cytokine mRNA transcripts
Total cytoplasmic RNAs was prepared as described 12 and 1 g was included in a 20 l cDNA synthesis reaction containing: reverse transcriptase buffer, 1 mm of each dNTP, 20 g/ml oligo-dT and 20 units Mo-MuLV reverse transcriptase. After incubation at 42°C for 40 min, the reaction was terminated by addition of H 2 O. For PCR amplification, 5 l of cDNA were included in a 50 l reaction mixture containing PCR buffer, dNTPs, 1-2 units Taq polymerase and 1 m of each oligonucleotide primer. The primers for murine IL-3 were: 5ЈAATCAGTGGCCGGGATACCC3Ј and 5ЈCGAAATCATCCA-GATCTCG3Ј defining a 200 bp cDNA fragment which could readily be distinguished from a genomic IL-3 DNA fragment by size (Ͼ1 kb). The primers for murine GM-CSF were: 5ЈCCTGAGGAGGATGTGGCTGC3Ј and 5ЈCTGTCCAAGCTG AGTCAGCG3Ј defining a 601 bp fragment. The primers for murine ␤ 2 -microglobulin were 5ЈTTCTCTCACTGACCGGCCT G3Ј and 5ЈCAGTAGACGGTCTTGGGCTC3Ј defining a 308 bp fragment. Forty cycles of PCR were performed to detect cytokine cDNAs. The PCR products were electrophoresed on 1% agarose gels and visualized after ethidium bromide staining of the gel.
Preparation of cell extracts and analysis by Western blotting
Cells were washed twice with cold PBS and lysed on ice in gold lysis buffer (GLB) containing 20 mm Tris (pH 7.9), 137 mm NaCl, 5 mm Na 2 EDTA, 1% (vol/vol) Triton X-100, 15% (vol/vol) glycerol, 1 mm phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 10 g/ml leupeptin, 1 m pepstatin A, 1 mm sodium orthovanadate, 1 mm ethylene glycol-bis (␤-aminoethyl ether)-N,N,NЈ,NЈtetra-acetic acid (EGTA), 10 mm sodium fluoride, 1 mm tetrasodium PP i , and 100 m ␤-glycerophosphate. Insoluble material was removed by centrifugation at 15 000 g as described. 16, [32] [33] [34] [35] [36] All chemicals were purchased from Sigma unless otherwise indicated. Cellular proteins were analyzed by electrophoresis through polyacrylamide SDS gels followed by Western immunoblotting on to polyvinylidene difluoride membranes (PVDF, Immobilon P; Millipore, Bedford, MA, USA). Western blots were incubated with the appropriate primary Ab at a dilution of 1:1000 to 1:2000 and then washed in Tris-buffered saline containing 0.5% (vol/vol) Nonidet P-40. Antigen-antibody complexes were visualized by using 1:10 000-diluted goat ␣-rabbit antiserum, sheep ␣-mouse antiserum, or protein A coupled to horseradish peroxidase as indicated in the enhanced chemiluminescence detection system (Amersham, Arlington Heights, IL, USA) as described. 16, [32] [33] [34] [35] [36] The blots were exposed to Kodak XAR5 X-ray film (Kodak, Rochester, NY, USA) for 30 to 60 s. The ␣BCL2 antibody (Santa Cruz Biotechnology (SCB), Santa Cruz, CA, USA) was directed to the N-terminus of the human BCL2 protein and recognizes both the human and murine BCL2 protein.
Determination of Raf kinase activity
The cells were grown in phenol red free DMEM (Life Technologies) containing charcoal-stripped FCS and the indicated supplements. Immune complexes of ⌬Raf:ER proteins were prepared by incubating cell lysates with an ␣-hbER Ab Leukemia (SCB) and protein A-sepharose 4B beads. Immune complexes were collected, washed three times in lysis buffer, and the activities of ⌬Raf:ER were assessed by incubation for 30 min at 30°C in a reaction mix containing 25 mm HEPES (pH 7.4), 10 mm MgCl 2 , 1 mm DTT, 50 m ATP and 10 m [␥-32 P]-ATP (3000 Ci/mmole, NEN) and 15 g of purified recombinant enzymatically inactive GST-MEK1 (Upstate Biotechnology (UPI), Lake Placid, NY, USA) as a substrate as described previously. 16, 35, 36 The reactions were analyzed by polyacrylamide gel electrophoresis and electrotransfer. The membranes were first exposed to X-ray film to quantitate GST-MEK1 phosphorylation and subsequently probed with an ␣-hbER Ab to quantitate the amount of the ⌬Raf:ER kinases present in each immunoprecipitate.
Determination of MEK activity
MEK activity was measured by immunoprecipitating the MEK1 proteins overnight with an ␣MEK1 Ab (SCB) and protein Asepharose 4B beads as described. 35 The immunoprecipates were then used in a kinase reaction for 30 min at 30°C in a reaction mix containing: 100 mm HEPES pH 7.4, 25 mm MgCl 2 , 1 mm DTT, 50 m ATP, 10 m [␥-
32 P]-ATP and 2 g of bacterially expressed rp44, an enzymatically inactive form of MAP kinase (ERK2, UBI). The reaction mixtures were electrophoresed through a 10% polyacrylamide gel, transferred to PVDF and exposed to X-ray film.
Determination of p42/44 MAPK (ERK1 and ERK2) activation and enzymatic activity
Cells were deprived of either IL-3 or ␤-estradiol for 24 h in phenol-red free medium that contained 5% charcoal-stripped BCS. Then the cells were pulsed with cytokine, different concentrations of ␤-estradiol or the positive control, 10 nm PMA, for varying periods of time. Cells were washed and resuspended in serum-free medium. One ml, containing 1.25 × 10 6 cells, was added to microfuge tubes and placed at 37°C for at least 1 h prior to the start of the treatment. Cells were stimulated or mock-stimulated by the addition of PMA, ␤-estradiol, IL-3, ethanol or DMSO to the tubes in a 10 l volume. Following stimulation for the indicated time, the tubes were centrifuged in a microcentrifuge for 30 s, the supernatants were removed, cell pellets were resuspended in 110 l of cold lysis buffer (25 mm Tris-HCl, pH 7.4; 50 mm NaCl; 0.5% sodium deoxycholate; 2% NP-40; 0.2% SDS; 1 mm phenymethylsulfonyl fluoride PMSF; 50 g/ml aprotinin, 50 m leupeptin; 0.5 mm Na 3 VO 4 ) and placed on ice for 15 min. Lysates were centrifuged for 15 min at 14 000 g in an Eppendorf microcentrifuge, supernatants (98 l) were removed and mixed with 42 l of 3.3× sample buffer (200 mm Tris-HCl, pH 6.8; 33% glycerol; 6.6% SDS; 16.6% ␤-mercaptoethanol; 0.04% bromophenol blue). Samples were boiled (5 min) and frozen. Fifteen microliters of prepared samples were electrophoresed through a 10% SDS-PAGE gel and proteins were electrophoretically transferred to PVDF membranes. Membranes were incubated overnight at 4°C in blocking buffer (25 mm Tris-HCl, pH 8.0; 125 mm NaCl; 0.1% Tween 20; 1% BSA; 0.1% sodium azide). Membranes were then incubated for 2 h with the primary antibody diluted in blocking buffer (anti-active MAP kinase, 1:20 000 (Promega, Madison, WI, USA) or anti-p90
Rsk (Santa Cruz), 1:10 000). The blots were washed twice in TBST (25 mm Tris-HCl, pH 8.0; 125 mm NaCl; 0.025% Tween 20) and -10 6 G418 r retroviruses/ml. b 1 × 10 5 cells were plated in each well of a 96-well plate 2 days post-infection in the presence of the indicated selective growth conditions. c Number of wells positive for growth/total number of wells examined. d LNL6 is a retroviral vector which lacks an oncogene. e FD/⌬A-Raf:ER(IL3)c2, FD/⌬B-Raf:ER(IL3)c1, and FD/⌬Raf-1:ER(IL3)c2 were determined to express the ⌬A-Raf:ER, ⌬B-Raf:ER, and ⌬Raf-1:ER kinases respectively, however, they were cytokine dependent clones. The number of times the particular infection was done is indicated by the total number of wells Ϭ 96. 
Results
Isolation of Raf-responsive cells after BCL2 infection of cytokine-dependent ⌬Raf:ER-infected cells
The overall design for the following experiments was to superinfect cytokine-dependent ⌬Raf:ER-infected FDC-P1 cells, with either an empty retroviral vector or a BCL2-containing retrovirus and determine whether BCL2 overexpression increased the frequency of isolation of Raf-responsive cells. As controls for the following experiments, the ability of a mock infection or infection with either BCL2 or the empty LNL6 retroviral vector to abrogate the cytokine dependency of FDC-P1 cells was determined. No viable cells were recovered after mock infection and culture in medium containing IL-3 + G418, ␤-estradiol + G418, or G418 indicating that the selection conditions were sufficient to kill uninfected cells. Furthermore neither BCL2 over-expression nor infection with an empty retroviral vector abrogated the cytokine dependency of FDC-P1 cells (Table 1) .
Previously we have demonstrated that after infection of FDC-P1 cells with retroviruses encoding ⌬A-Raf:ER, ⌬B-Raf:ER, and ⌬Raf-1:ER, cytokine-dependent puro r cells were recovered. 37 The clones were determined to contain the ⌬Raf:ER proteins by Raf kinase and Western blot assays (Figure 2 ). The ⌬Raf:ER expression was induced by ␤-estradiol. Therefore, expression of ⌬Raf:ER is increased in the presence of ␤-estradiol possibly due to an increase in protein stability. An example of the Raf kinase assay and subsequent Western blot is presented in Figure 2 . Endogenous Raf activity is induced by the addition of IL-3. However, the Raf assay that was used in these experiments was specifically designed to detect Raf activity associated with the ⌬Raf:ER proteins as an ␣ER Ab protein is used to immunoprecipitate the ⌬Raf:ER proteins and then a Raf assay is preformed. Equal loading of the proteins was determined by electrophoresis of the same samples and performing Western blot analysis with antibodies to the MEK1 and ERK2 proteins.
The cytokine-dependent FD/⌬A-Raf:ER(IL3)c2, FD/⌬B-Raf:ER(IL3)c1 and FD/⌬Raf-1:ER(IL3)c2 were subsequently infected with either a BCL2-containing retrovirus or the empty retroviral vector LNL6. Raf-responsive cells were isolated by plating the cells in the presence of G418 and ␤-estradiol in the absence of exogenous cytokines (Table 1) . More (four-to eight-fold) Raf-responsive cells were recovered after infection of FD/⌬A-Raf:ER, FD/⌬B-Raf:ER and FD/⌬Raf-1:ER cells with the BCL2 than after infection with the LNL6 empty retroviral vector.
To determine whether similar results could be obtained by were isolated from ⌬Raf:ER-infected FDC-P1 cells, 3.8-fold more Raf-responsive cells were recovered from the BCL2 and ⌬Raf-1:ER-infected cells (Table 2) .
Cytokine-dependent FD/LNL6 + FD/BCL2 cells were also infected with a GFP⌬Raf-1:ER construct containing the green fluorescent protein (GFP) linked to the ⌬Raf-1:ER. After infection of FD/BCL2 cells with the GFP⌬Raf-1:ER retrovirus, a similar frequency of Raf-responsive cells was recovered as after infection with the ⌬Raf-1:ER retrovirus ( Table 2 ). The GFP tag in the GFP⌬Raf-1:ER construct allows rapid examination of the GFP⌬Raf-1:ER expression by FACS analysis in cells which are cytokine-dependent vs those that are Rafresponsive ( Figure 3 ). As controls, the levels of background fluorescence were determined in cells which did not have the GFP⌬Raf-1:ER (Figure 3a-d) . These cells had a single peak of (g and h) . Growth in medium containing: IL-3 (í), ␤-estradiol (̆) or no supplement (b). Dotted line equals 37% of wells negative for growth from which the differential plating efficiency was estimated by Poisson distribution. Solid arrow on the X-axis indicates where the experimental data line intersects with the 37% negative for growth line and is an estimate of the cloning efficiency. These experiments were performed on three to five pools isolated from each type of ⌬Raf:ER-infected cells. Determined by Poisson analysis as presented in Figure 4 . fluorescence as determined by FACS analysis which did not significantly change when the cells were cultured in IL-3 or IL-3 + ␤-estradiol. The expression of the GFP⌬Raf-1:ER protein was heterogenous in the cytokine-dependent FD/BCL2+GFP⌬Raf-1:ER (IL3) pool, with about one-half of the cells positive for expression and one-half negative for GFP⌬Raf-1:ER expression (Figure 3e) . Culture of these cells for 24 h in the presence of IL-3 + ␤-estradiol increased GFP⌬Raf-1:ER expression as a more fluorescent shoulder was present (Figure 3f ). In contrast, the Raf-responsive FD/BCL2+GFP⌬Raf-1:ER(Est) clones were more fluorescent and homogenous than the cytokine-dependent cells. Two Rafresponsive clones are shown in Figure 3 , similar results were observed with 12 other clones.
Frequency of isolation of Raf-responsive cells from pools of ⌬Raf:ER and BCL2-infected FDC-P1 cells
To determine the frequency of isolation of Raf-responsive cells from ⌬Raf:ER and BCL2 infected FDC-P1 cells, limiting dilution analyses were performed on the cells isolated in the presence of IL-3 + G418 ( Figure 4 ). As controls, the abilities of FDC-P1 cells infected with the empty retroviral vector (Figure 4a ) or the BCL2 (Figure 4b ) viruses to give rise to factor-independent cells were determined. No cytokine-inde- Leukemia pendent cells were isolated from these infected cells. In Figure  4c , e and g, limiting dilution analysis of ⌬Raf:ER and empty retroviral vector (LNL6) infected cells are presented. In Figure  4d , f and h, the limiting dilution analysis of ⌬Raf:ER and BCL2 infected cells are presented. Depending upon which ⌬Raf:ER oncoprotein the cells were infected with, BCL2 overexpression increased the frequency of isolation of FD/⌬Raf:ER cells that grew in response to ⌬Raf:ER activation five-to 100-fold (Figure 4d , f and h) in comparison to cells that were infected with the empty retroviral vector (Figure 4c , e and g) ( Table 3 ). The major reason why there were higher frequencies of Raf-responsive cells in these experiments as opposed to those presented in Tables 1 and 2 is that pools of 100% infected cells were examined, whereas in Tables 1 and  2 , not all the cells were infected with either BCL2 or LNL6.
Thus, six different types of cells were isolated after these infection experiments: (1) cells which were infected with the empty retroviral vectors (LNL6 or pBP3puro) and remained cytokine-dependent; (2) cells which expressed just the BCL2 oncogene that remained cytokine-dependent; (3) cells which expressed the ⌬Raf:ER genes that remained cytokine-dependent; (4) cells which expressed the BCL2 and ⌬Raf:ER genes and remained cytokine-dependent; (5) cells which expressed the ⌬Raf:ER genes that grew in response to the Raf proteins in the absence of exogenous cytokines; and (6) cells which expressed the BCL2 and ⌬Raf:ER genes that grew in response Leukemia to the Raf proteins in the absence of exogenous cytokines.
Growth properties of BCL2 and ⌬Raf:ER Infected FDC-P1 cells
To determine the growth properties of the cells which overexpressed the BCL2 and ⌬Raf:ER oncoproteins, growth curve experiments were performed. Cytokine-dependent ⌬Raf:ERinfected cells required IL-3 to proliferate (Figure 5a, d and g ). Addition of ␤-estradiol did not stimulate growth in these cells. In contrast, ␤-estradiol did promote cell growth in the Rafresponsive FD/⌬A-Raf:ER+LNL6(Est)c2 (Figure 5b 
Ability of ␤-estradiol and IL-3 to stimulate [
3
H]-thymidine incorporation in BCL2 and ⌬Raf:ER-infected hematopoietic cells
Stimulation of [ 3 H]-thymidine incorporation by antiestrogens
To determine whether the estrogen-receptor antagonist 4-OH tamoxifen (4-HT) also promoted growth, similar dose- 
Effects of ⌬Raf:ER and BCL2 expression on cell cycle progression
The Raf and downstream MEK and ERK activities have been shown to influence cell cycle progression by regulating the expression of the p21
Cip1 cell cycle inhibitory protein as well as growth stimulatory proteins. 1, 16, 65, 67 Cell cycle progression can be examined by starving cytokine-dependent cells for IL-3 or in this case ␤-estradiol, and then determining the extent Modfit histogram analysis of cell cycle distribution. Cell cycle progression in Raf-responsive FD/⌬Raf-1:ER+LNL6(Est)c2 cells (A); cell cycle progression in Raf-responsive FD/⌬Raf-1:ER+BCL2(Est)c2 cells (B). In these histograms, the Y axis (the cell number) was cut off at 500 in order to display the proportion of cells in S and G 2 /M better. The actual percentages of the cells in the different phases were determined from the original data graphs and are presented in Effects of Raf and BCL2 on cell cycle progression in FDC-P1 cells. The percentages of cells in the G 1 , S and G 2 /M phases of the cell cycle of the indicated cell lines were statistically determined by the Modfit computer program after deprivation of cytokine or ␤-estradiol and then treatment with either IL-3 (), tamoxifen (̅) or no addition (ć). (Top A panels) the three types of FD/⌬A-Raf:ER cells (panels A1-A9); (middle B panels) the three types of FD/⌬B-Raf:ER cells (panels B1-B9); and (bottom C panels) the three types of FD/⌬Raf:ER cells (panels C1-C9). −24 indicates the start of the experiments, 0 indicates when either IL-3 or tamoxifen were added. Panels A1-A3, cytokine-dependent FD/⌬A-Raf:ER(IL3)c2; panels A4-A6, Raf-responsive FD/⌬A-Raf:ER+LNL6(Est)c2; panels A7-A9, Rafresponsive and BCL2-infected FD/⌬A-Raf:ER+BCL2(Est)c2; panels B1-B3, cytokine-dependent FD/⌬B-Raf:ER+LNL6(IL3)c1; panels (B4-B6) FD/⌬B-Raf:ER+LNL6(Est)c1; panels B7-B9, Raf-responsive and BCL2 infected FD/⌬B-Raf:ER+BCL2(Est)c1; panels C1-C3, cytokinedependent FD/⌬Raf-1:ER+LNL6(IL3)c1; panels C4-C6, Raf-responsive FD/⌬Raf-1:ER+LNL6(Est)c1; and panels C7-C9, Raf-responsive and BCL2-infected FD/⌬Raf-1:ER+BCL2(Est)c1 cells. These experiments were repeated three to six times and then averaged together. In those cases where the error bars are not visible, the standard deviations are contained within the size of the symbols.
of cell cycle progression after addition of IL-3 or tamoxifen. In these experiments, tamoxifen was used in place of ␤-estradiol because tamoxifen is a pure estrogen receptor antagonist and therefore the effects of estrogen on cell cycle progression will not confuse the effects of Raf on cell cycle progression. Exponentially growing cells were collected, washed three times with PBS and cultured in phenol red free medium containing 5% FCS in the absence of IL-3 and ␤-estradiol. −24 h indicates the start of the experiments. Then after 24 h of ␤-estradioldeprivation, IL-3, tamoxifen, or nothing was added to the cells and cell aliquots were removed every 12 h. A diagrammatic example of the effects of ⌬Raf-1:ER on cell cycle progression is presented in Figure 8 .
We Figure 9 . Cells deprived of ␤-estradiol for 12 h (−12 h) are shown in Figure 8b (A and B) . Cells deprived of ␤-estradiol for 24 h are shown in the Figure 8c (A and B) . The Raf-responsive FD/⌬Raf-1:ER+LNL6(Est)c2 exit the S and G 2 /M phases after 12 to 24 h of ␤-estradiol deprivation ( Figure 8A (b and c) . In contrast, a significant proportion of the FD/⌬Raf: ER+BCL2(Est)c2 cells remained in the S and G 2 /M phases after 12 or 24 h of ␤-estradiol withdrawal ( Figure 8B (b and c) . However, after culture of these cells for 48 or 72 h in the absence of ␤-estradiol, the cells were predominantly in the G 1 phase ( Figure 8B (d and g) . Once either IL-3 or tamoxifen was added, both types of Raf-responsive cells entered the cell cycle ( Figure 8A and B) (e, h, f, i) .
The cell cycle progression profiles in the cytokine-dependent and Raf-responsive ⌬Raf and BCL2 infected FDC-P1 cells are presented graphically in Figure 9 . These experiments represent the average of three to six time course experiments. Initially (designated −24h) approximately 25% of the IL-3-dependent and Raf-responsive cells were in the S phase of the cell cycle (Figure 9 After 24 h of cytokine-deprivation, at T 0 , the cells were treated with IL-3, tamoxifen or nothing and the percentages of cells in the different phases of the cell cycle were determined at 12 h intervals. The main difference between the cytokine-dependent FD/⌬Raf:ER, Raf-responsive FD/⌬Raf:ER + LNL6 and Raf-responsive FD/⌬Raf:ER+BCL2 cells was that very few cytokine-dependent FD/⌬A-Raf:ER, FD/⌬B-Raf:ER or FD/⌬Raf-1:ER cells entered the cell cycle after tamoxifen treatment whereas the Raf-responsive cells entered S phase after tamoxifen treatment ( Figure 9A4 , B4 and C4). It should be noted that a small percentage of the cytokine-dependent FD/⌬Raf-1ER(IL3)c1 cells entered S phase (12%, Figure 9C2 ) and G 2 /M phases (5%, Figure 9C3 ) after tamoxifen treatment.
The effects of estradiol deprivation were examined in the Raf-responsive cells. The Raf-responsive FD/⌬A-Raf:ER+LNL6 (Est)c2, FD/⌬B-Raf:ER+LNL6(Est)c1 or FD/⌬Raf-1:ER+LNL6 (Est)c1 cells exited the cell cycle upon removal of tamoxifen. These cells entered the S phase ( Figure 9A5 , B5 or C5) and G 2 /M phases ( Figure 9A6 , B6 or C6) of the cell cycle upon addition of either IL-3 or tamoxifen. Interestingly the FD/⌬A-Raf:ER+LNL6(Est)c2 cells showed the most dramatic response to tamoxifen treatment in terms of entry into S phase ( Figure  9A5) and exit from the G 1 phase ( Figure 9A4 ) after tamoxifen treatment. The Raf-responsive FD/⌬B-Raf:ER+LNL6(Est)c1 cells showed a more modest re-entry into the cell cycle after either IL-3 or tamoxifen treatment ( Figure 9B5 and B6) .
The cell cycle progression parameters were examined in the Raf-infected cells which also had BCL2. In the Raf-responsive FD/⌬A-Raf:ER+BCL2(Est)c2 cells, the cells exited the S phase ( Figure 9A8 ) and G 2 /M ( Figure 9A9 ) phase after ␤-estradiol withdrawal for 24 h. The cells accumulated in the G 1 phase ( Figure 9A7 ). The FD/⌬A-Raf:ER+BCL2(Est)c2 re-entered the S and G 2 /M phases approximately 24 h after addition of either tamoxifen or IL-3.
Some Raf-responsive FD/⌬B-Raf:ER+BCL2 cells exited S phase 24 h after ␤-estradiol deprivation (Figure 9B8 ), however, approximately 14% remained in S phase which was significantly higher than the percentage of cytokine-dependent or Raf-responsive FD/⌬B-Raf:ER cells ( Figure 9B2 and B5) which remained in S phase 24 h after either cytokine or ␤-estradiol deprivation. After ␤-estradiol withdrawal and subsequent treatment with either IL-3 or tamoxifen, the FD/⌬B-Raf:ER+BCL2 cells showed less dramatic effects on cell cycle distribution than either the FD/⌬A-Raf:ER+BCL2(Est)c2 or FD/⌬Raf-1:ER+BCL2(Est)c1 cells.
Finally the cell cycle distribution was analyzed in the Rafresponsive FD/⌬Raf-1:ER+BCL2(Est)c1 cells ( Figure 9C7-C9) . The percentages of cells in S phase decreased from approximately 25 to 8% after ␤-estradiol withdrawal for 24 h. This was not as low a percentage as that observed in ␤-estradiolstarved Raf-responsive FD/⌬Raf-1:ER cells ( Figure 9C5 ). After 36 to 72 h of ␤-estradiol withdrawal, almost all the Rafresponsive FD/⌬Raf-1:ER+BCL2 cells had exited the S and G 2 /M phases of the cell cycle ( Figure 9C8 ). The proportion of cells in G 1 increased upon cytokine withdrawal from 65 to 90%. Furthermore, these FD/⌬Raf-1:ER+BCL2(Est) cells showed a gradual exit from S phase until after 24 h addition of IL-3 or tamoxifen. Addition of either tamoxifen or IL-3 to the FD/⌬Raf:ER+BCL2 cells for 24 h resulted in the cells exiting G 1 and accumulating in the S and G 2 /M phases of the cell cycle ( Figure 9C7, C8 and C9) .
Expression of the GFP⌬Raf:ER protein in the Rafresponsive cells
We next wanted to determine what was happening to the level of the GFP⌬Raf-1:ER protein when the cells were deprived of ␤-estradiol and then subsequently treated with either ␤-estradiol or IL-3. The expression of the GFP⌬Raf:ER protein was compared in the Raf-responsive FD/LNL6+GFP⌬Raf-1:ER(Est)c2
and FD/BCL2+GFP⌬Raf-1(Est)c2 cells upon ␤-estradiol deprivation and subsequent treatment with ␤-estradiol and IL-3. Two different negative controls were used in these experiments, in Figure 10 , top panel 1A, the autofluorescence of FD/LNL6 cells is shown, in Figure 10 , bottom panel 1A, the autofluorescence of Rafresponsive FD/⌬Raf-1:ER(Est)c2 cells is shown.
The fluorescence profiles of the FD/LNL6+GFP⌬Raf-1:ER(Est)c2 and FD/BCL2+GFP⌬Raf-1:ER(Est)c2 cells cultured in ␤-estradiol continuously are shown in Figure 10 , top and bottom panels 2E, 3E, 4E and 5E, respectively. When the FD/LNL6 +GFP⌬Raf:ER cells were starved of ␤-estradiol for 24 h, the mean fluorescence of the GFP⌬Raf-1:ER protein decreased over four-fold (compare Figure 10 , top panels 1B and 2E). In contrast, when the FD/BCL2+GFP⌬Raf-1:ER(Est)c2 cells were deprived of ␤-estradiol the change in GFP⌬Raf-1:ER expression was less dramatic as less than a two-fold decrease in mean fluorescence was observed ( Figure 10 , bottom panels 1B and 2E).
The expression of the GFP⌬Raf-1:ER protein was examined in the two different cell lines after treatment with IL-3 or ␤-estradiol. IL-3 did not increase the level of GFP⌬Raf-1:ER expression in either the FD/LNL6+GFP⌬Raf-1:ER(Est)c2 ( Figure 10 , top panels 2B, 3B, 4B or 5B) or FD/BCL2+GFP⌬Raf-1(Est)c2 (Figure 10 , bottom panels 2B, 3B, 4B or 5B) cells, although the cells proliferated under these conditions. In contrast, addition of ␤-estradiol increased the level of GFP⌬Raf-1:ER expression in both types of cells after approximately 7 h of treatment ( Figure 10 , top and bottom panels 4C, 4D, 5C and 5D). Moreover, the cells which had BCL2 obtained a level of GFP⌬Raf-1:ER expression similar to that observed in the cycling cells faster after ␤-estradiol withdrawal and subsequent treatment with ␤-estradiol (Figure 10 , bottom panel 5D vs 2E) than the Raf-responsive cells which lacked BCL2 (Figure 10, top panel 5D vs 2E) . Thus the recovery period for GFP⌬Raf-1:ER expression was shorter in the cells which overexpressed BCL2.
Effects of ⌬Raf:ER on Raf and MEK activities
The GFP fluorescence studies indicated that the levels of the GFP⌬Raf-1:ER protein were sensitive to ␤-estradiol withdrawal but they did not determine what happened to the Raf enzymatic activity in these culture conditions. For the conditionally active Raf kinases to be effective, they should induce Raf as well as downstream MEK and ERK activities. To determine whether this was the case in the ⌬Raf:ER and BCL2 infected cells, Raf and downstream kinase assays were performed. The Raf assays were performed on ⌬Raf:ER immunprecipitated proteins recovered from the cells grown for 24 h under the different conditions (Figure 11) .
When Raf or Raf+BCL2 infected cells were grown in the absence of ␤-estradiol for 24 h (either no addition (−) or + IL-3) either no or very low levels of Raf kinase activity were detected. When FD/⌬Raf:ER+BCL2(Est)c2 cells were cultured in IL-3, a very low level of ⌬Raf:ER kinase was detected. However when the cells were cultured with ␤-estradiol (IL-3 and ␤-estradiol or ␤-estradiol alone) a significant increase in Raf activity was detected in all the Raf-responsive cell lines. For comparison purposes, the levels of Raf and MEK activities in Raf-responsive ⌬Raf:ER and ⌬Raf:ER+BCL2 infected cells are shown. The levels of ⌬Raf:ER proteins varied dramatically in the different culture conditions in the Raf-responsive cells which lacked exogenous BCL2 (Figure 11a , c, and e) whereas the Raf and BCL2 infected cells displayed similar levels of ⌬Raf:ER proteins under the different culture conditions ( Figure  11b, d and f) .
The levels of MEK1 activity were determined in the same samples. Higher levels of MEK1 activity were detected when the cells were treated with ␤-estradiol (IL-3 + ␤-estradiol or ␤-estradiol alone) than when the cells were treated with IL-3. Thus the introduced ⌬Raf:ER proteins induced Raf and downstream MEK activity.
To determine the requirement of the MEK1 activity for the growth of the Raf and BCL2-infected cells, they were treated with the MEK inhibitor PD98059 and the effects on proliferation examined (Figure 12 ). The MEK1 inhibitor suppressed The effects of MEK1 inhibitor PD98059 on MEK1 activity were determined in Raf-responsive FD/⌬A-Raf:ER(Est)c2 and FD/⌬A-Raf:ER+BCL2 cells ( Figure 13 ). The MEK1 inhibitor did not reduce Raf activity in either FD/⌬A-Raf:ER+LNL6(Est)c2 ( Figure 13, lane 2) or FD/⌬A-Raf:ER+BCL2(Est)c2 ( Figure 13 , lane 2). In contrast after treatment with the MEK1 inhibitor, the MEK activity was decreased in both cell lines.
Effects of IL-3 and ␤-estradiol on ERK2 activation and activity in FD/⌬Raf:ER+BCL2(Est) cells
To determine whether the activated Raf oncoproteins induced down-stream ERK2 activation, cells were deprived of ␤-estradiol for 24 h and then treated with either IL-3 or ␤-estradiol for . h (Figure 14a) . Treatment of the cells with IL-3, ␤-estradiol or the control phorbol esters resulted in activation of ERK1 and ERK2. To determine the requirement of functional MEK1 proteins in the activation of ERK1 and ERK2 in these cells, the cells were treated with the MEK1 inhibitor PD98059. Treatment with PD98059 eliminated Raf-induced ERK1 and ERK2 activation.
It should be noted that treatment with the MEK1 inhibitor did not suppress all of the PMA induced ERK1,2 activation. The PD98059 inhibition is not 100% complete, as the PMA induces such a strong signal that it is not completely blocked by the MEK1 inhibitor. In addition, PMA may phosphorylate ERK1,2 through a MEK1-independent mechanism. As a control the upper portion of the blots were probed with an ␣p90
Rsk Ab. Relatively equal levels of p90 Rsk proteins were detected in the samples. Hyperphosphorylation of p90
Rsk was readily observed after PMA and ␤-estradiol treatment indicating that Raf and PKC induced p90
Rsk phosphorylation. Treatment of the cells with the MEK1 inhibitor eliminated p90 Rsk hyperphosphorylation after ␤-estradiol but not PMA treatment providing further evidence that PMA can induce a pathway which is independent of MEK1 activity.
To determine the effects of Raf on ERK2 kinase activity, an 
Expression of the BCL2 oncoprotein in the FD/⌬Raf:ER + BCL2 infected cells
It was important to confirm that the cells which were infected with the BCL2 retrovirus actually expressed the BCL2 oncoprotein. In the pool of cytokine-dependent FD/BCL2+ GFP⌬Raf-1:ER cells, a low level of BCL2 expression was detected after immunoprecipitation and Western blot analysis with the ␣BCL2 antibody (Figure 15a ). These cytokine-dependent cells had not been selected for factor-independence. In contrast in the Raf-responsive FD/BCL2+⌬Raf-1:ER cells there was a higher level of BCL2 expression suggesting that increased BCL2 expression was associated with abrogation of cytokine-dependency in these cells (Figure 15b ). BCL2 expression was also examined in the different Raf-responsive FD/⌬Raf:ER cells. Some Raf-responsive cells contained BCL2, whereas the FD/⌬Raf-1:ER+LNL6(Est)c2 cell line did not. The level of BCL2 expression was lower in the FD/⌬Raf-1:ER(Est)c1 cells (Figure 15c ) than in the Raf-responsive cells which had BCL2 namely FD/⌬A-Raf:ER+BCL2(Est)c2 (Figure  15d ), FD/⌬B-Raf:ER+BCL2(Est)c1 (Figure 15e ) or FD/⌬Raf-1:ER+BCL2(Est)c2 (Figure 15f) . Thus the cells which were Rafresponsive and infected with BCL2 expressed more BCL2 protein than the cells that were either Raf-responsive and not infected with the BCL2 oncoprotein or the cytokine-dependent FD/BCL2+GFP⌬Raf-1:ER pool. 
Autocrine growth factor synthesis by BCL2 and ⌬Raf:ER infected cells
To determine whether there was a possible autocrine component to the growth induced by ⌬Raf:ER, the presence of autocrine growth factor synthesis was examined by RT-PCR ( Figure 16 ). cDNAs encoding GM-CSF and IL-3 were detected in the control T cell thymoma EL4 and increased levels were detected when these cells were stimulated with the phorbol ester PMA for 24 h. cDNAs encoding IL-3 and GM-CSF were not detected in the parental FDC-P1 line or the cytokinedependent ⌬Raf:ER-infected cells. cDNAs encoding GM-CSF but not IL-3 were detected in the Raf-responsive cells implicating a possible autocrine mechanism of transformation. These
Figure 14
Raf induces ERK and p90 Rsk activation in Raf-responsive ⌬RAF-ER and BCL2 infected cells. (a) FD/⌬Raf-1:ER+LNL6 (Est)c2 cell lysates were prepared from ␤-estradiol-starved cells that were stimulated with IL-3, ␤-estradiol or PMA. As a loading control, the upper portions of the blots were probed with the ␣-p90
Rsk Ab (bottom panel) to determine the levels of p90 Rsk protein. Aliquots of the same cells were also starved for ␤-estradiol in the presence of 25 m PD98059 for 24 h. ERK activation was also examined in these cells. (b) ERK2 activity in FD/⌬Raf-1:ER+BCL2(Est)c2 cells that had been starved of ␤-estradiol for 24 h and then treated with either IL-3 or ␤-estradiol for the indicated times.
Figure 15
Expression of the BCL2 oncoprotein in the ⌬Raf:ER and BCL2 infected cells. The expression of the BCL2 oncoprotein was determined by immunoprecipitating BCL2 with an ␣BCL2 Ab and followed by Western blot analysis.
GM-CSF transcripts were detected in all Raf-responsive cells, whether or not the cells were infected with BCL2.
To determine whether these GM-CSF transcripts resulted in the expression of GM-CSF protein, the abilities of the supernatants prepared from the Raf-responsive ⌬Raf:ER+BCL2 infected cells to stimulate [ Expression of autocrine GM-CSF cDNAs in BCL2 and ⌬Raf:ER cells. RT-PCR analysis was performed on mRNA samples from the cells grown under the indicated conditions. The EL-4 thymoma was used as a control. Higher levels of GM-CSF cDNA transcripts were detected when EL-4 cells were stimulated with PMA than in unstimulated EL4 cells. Similar amounts of mRNAs were used in the RT-PCR analysis as determined by the relatively equal levels of ␤ 2 -microglobulin detected. 
Discussion
After infection of hematopoietic cells with ⌬Raf:ER containing retroviruses, two different types of cells were isolated, cytokine-dependent or Raf-responsive, both types of cells expressed the ⌬Raf:ER oncoprotein. The cytokine-dependent ⌬Raf:ER cells died after IL-3 withdrawal for 24 to 48 h. ␤-Estradiol would not replace this requirement of IL-3 for growth in the cytokine-dependent cells even though they expressed the ⌬Raf:ER encoded kinases. These results implied that another genetic event was required for the Raf-responsive growth of FDC-P1 cells. The growth of the Raf-responsive ⌬Raf:ER infected cells was conditional as removal of ␤-estradiol eliminated growth and induced apoptosis. 37 This indicated that the activated ⌬Raf:ER oncoprotein was necessary for Raf-responsive growth. Moreover, the Raf-responsive cells exited the cell cycle after ␤-estradiol withdrawal similar to the cytokine-dependent ⌬Raf:ER-infected cells after IL-3 withdrawal. However, Raf activation was able to promote entry into the S and G 2 /M phases in the Raf-responsive but not in the cytokine-dependent cells.
We are interested in determining which genes may be capable of synergizing with Raf and result in the abrogation of cytokine dependency. One relatively simple and fast approach is to examine the ability of known oncogenes to increase the frequency of abrogation of cytokine dependency of ⌬Raf:ER infected cells. The BCL2 oncogene was an obvious choice since it has been shown to interact with Raf and is a target for downstream ERK2. Thus we determined the ability of BCL2 oncogene expression to synergize with ⌬Raf:ER expression and increase the frequency of Raf-responsive cells. While BCL2 expression by itself did not abrogate cytokine independence, BCL2 overexpression in conjunction with ⌬Raf:ER expression increased the frequency of cytokine-independent cells. Functional Raf expression was necessary as cytokine-independent cells were not recovered from FDC-P1 cells infected with BCL2 alone or FD/BCL2 subsequently infected with the kinase-inactive ⌬Raf-1[301]:ER mutant. Moreover higher levels of BCL2 expression were detected in the Raf and BCL2 infected cells which grew in response to Raf. Overexpression of BCL2 is probably not the reason why all the Raf-responsive cells grow in response to Raf as the FD/⌬Raf-1:ER+LNL6(Est)c2 cells did not overexpress BCL2. However, that does not eliminate the importance of these results as we have observed that some MEK1-responsive cells do overexpress BCL2 (see accompanying article, this issue, pp 1080-1096). There may be other anti-apoptotic molecules (eg Bcl-X L , A1) which are over-expressed in the Raf-responsive FD/⌬Raf:ER+LNL6 cells. Alternatively certain pro-apoptotic molecules may be expressed at lower levels thus increasing the anti-apoptotic effects of BCL2.
A significant difference between the Raf-responsive FD/⌬Raf-1:ER+LNL6(Est)c2 and FD/⌬Raf-1:ER+BCL2(Est)c2 was that the Raf-responsive cells which contained exogenous BCL2 displayed a delayed exit from the S phase ( Figure 9C8 ) and G 2 /M ( Figure 9C9 ) phases of the cell cycle when they were deprived of ␤-estradiol. Thus BCL2 was impeding the exit of FD/⌬Raf-1:ER+BCL2 cells from the cell cycle after ␤-estradiol withdrawal. The combination of BCL2 overexpression and autocrine GM-CSF expression may keep a higher proportion of these cells in the S and G 2 /M phases than those cells which lacked BCL2 overexpression. Another observation from these experiments was that activation of Raf in the Raf-responsive FD/⌬A-Raf:ER(Est)c2 and FD/⌬Raf-1:ER(Est)c2 cells often resulted in a more robust entry into S and exit from G 1 than after stimulation with IL-3 ( Figure 9 panels A4, A5, A7, A8, C7 and C8). This may have resulted from the cells being selected to grow in response to Raf which can cause a down regulation of the IL-3 receptors (data not presented) (Figure 8 ). Moreover the change in the level of GFP/⌬Raf-1:ER protein upon ␤-estradiol withdrawal was decreased in the cells which had BCL2 in comparison to the cells which did not. Therefore BCL2 was exerting a protective effect on the cells.
Raf induced autocrine growth factor expression. The GM-CSF expression was due to Raf and not BCL2 expression as autocrine GM-CSF transcripts were observed in Raf-responsive cells which lacked BCL2 expression. Raf may be inducing the phosphorylation of downstream transcription factors which bind the GM-CSF promoter region and stimulate GM-CSF expression. A model for this stimulation of autocrine GM-CSF expression by the activation of the Raf/MEK/ERK pathway was presented in Figure 1 .
These cells provide an interesting model to elucidate the effects of the different Raf kinases hematopoietic cell growth, prevention of apoptosis and malignant transformation. Identification of pathways which cross-talk with the Ras/Raf/MEK/MAPK pathway to promote cellular transformation and prevent apoptosis will aid in our understanding of the mechanisms responsible for tumor progression.
